Literature DB >> 16857270

MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS).

Rongzhen Zhang1, Ron Gascon, Robert G Miller, Deborah F Gelinas, Jason Mass, Mariselle Lancero, Amy Narvaez, Michael S McGrath.   

Abstract

Recent studies suggest that monocyte activation may play a role in ALS pathogenesis. Therefore, monocyte CCR2, the receptor for monocyte chemoattractant protein-1 (MCP-1), and plasma levels of MCP-1 were measured in 42 sALS patients, 38 healthy and 34 age-related macular degeneration (ARMD) controls. MCP-1 was elevated in both sALS and ARMD patients, but CCR2 levels were significantly decreased on sALS but not on ARMD monocytes. Loss of monocyte CCR2 expression was inversely correlated with degree of monocyte/macrophage activation in sALS and this decrease was unlikely due to receptor down-regulation given the ARMD results. Defective monocyte/macrophages may play an active role in sALS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857270     DOI: 10.1016/j.jneuroim.2006.06.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  31 in total

Review 1.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

Review 2.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

Review 3.  Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.

Authors:  Diane Moujalled; Anthony R White
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

Review 4.  Differential contribution of microglia and monocytes in neurodegenerative diseases.

Authors:  Caroline Baufeld; Elaine O'Loughlin; Narghes Calcagno; Charlotte Madore; Oleg Butovsky
Journal:  J Neural Transm (Vienna)       Date:  2017-10-23       Impact factor: 3.575

5.  Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS).

Authors:  Rongzhen Zhang; Kenneth G Hadlock; Hien Do; Stephanie Yu; Ronald Honrada; Stacey Champion; Dallas Forshew; Catherine Madison; Jonathan Katz; Robert G Miller; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2010-09-29       Impact factor: 3.478

6.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

7.  Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).

Authors:  Rongzhen Zhang; Robert G Miller; Ron Gascon; Stacey Champion; Jonathan Katz; Mariselle Lancero; Amy Narvaez; Ronald Honrada; David Ruvalcaba; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2008-11-14       Impact factor: 3.478

8.  Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.

Authors:  Benjamin J Murdock; Tingting Zhou; Samy R Kashlan; Roderick J Little; Stephen A Goutman; Eva L Feldman
Journal:  JAMA Neurol       Date:  2017-12-01       Impact factor: 18.302

9.  NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study.

Authors:  Robert G Miller; Rongzhen Zhang; Gilbert Block; Jonathan Katz; Richard Barohn; Edward Kasarskis; Dallas Forshew; Vidhya Gopalakrishnan; Michael S McGrath
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-09-05       Impact factor: 4.092

10.  The Neuroinflammatory Response in ALS: The Roles of Microglia and T Cells.

Authors:  Coral-Ann Lewis; John Manning; Fabio Rossi; Charles Krieger
Journal:  Neurol Res Int       Date:  2012-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.